CLOs on the Move

Midwest AgEnergy Group

www.midwestagenergygroup.com

 
Midwest AgEnergy Group is a North Dakota biofuels enterprise. Midwest AgEnergy Group owns Blue Flint Ethanol, a 65 million gallon per year biorefinery in operation since 2007 near Underwood, N.D., and Dakota Spirit AgEnergy, a 65 million gallon per year biorefinery east of Jamestown, ND that began production in June 2015. Together with our partners, we are building a renewable energy future for the country, increasing demand for North Dakota farmers, and bringing prosperity to our communities.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

K-LaB Technologies

K-LaB Technologies, Inc. is a Dripping Springs, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Simplex Sciences

High quality, reliable single-stranded DNA ladders from Simplex Sciences. 10, 20, 50, and 100 base increment ladders are available, with new products coming soon.

Novaseek Research

Novaseek is transforming how biomedical researchers access real-world hospital patient data and human biospecimens. Researchers rely on Novaseek to plan projects, and procure high quality biospecimens and clinical data needed to power discovery. Increasing productivity and de-risking projects across R&D enterprise begins with NovaSeek!

Ash Stevens Inc

Founded in 1962, Ash Stevens is a premier contract research organization that provides low-volume, high-value Active Pharmaceutical Ingredients (APIs). We understand the industry needs and utilize our expertise in pharmaceutical regulatory affairs to

Gradalis

Gradalis, Inc. is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of drugs, vaccines, tools, and diagnostics primarily in the area of cancer. Gradalis has its own GMP manufacturing facility along with highly skilled technical leadership and staff and a strategic partnership with Mary Crowley Cancer Research Centers for clinical development of Gradalis products. The Company has two primary platforms, one centered on personalized autologous vaccines and a second focused on bifunctional short hairpin RNA (shRNA) to enable specific protein knockdown. In addition. Gradalis has numerous partnerships and joint ventures that provide it with access to other cutting edge clinical and pre-clinical stage programs.